If you're looking at the financial performance of Neuren in the near term then this year will be less than last and next year is possibly a lot worse if you assume they won't make the $500 million annual sales milestone. So from that POV a drop in share price can be justified but it completely discounts the success with 2591 and the fact that there will be continued growth in Daybue sales as more very young patients are diagnosed and Canada and Europe come online. I'm playing the long game and view this as a buying opportunity because the Phase 2 results should be replicable in a larger study and any successful Phase 3 mean 2591 can't be ignored any more and will add billions to Neuren's estimated value.
NEU chart, page-1895
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B |
Open | High | Low | Value | Volume |
$13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2300 | $12.93 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.96 | 2086 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2300 | 12.930 |
1 | 775 | 12.900 |
1 | 192 | 12.890 |
2 | 1877 | 12.800 |
2 | 578 | 12.780 |
Price($) | Vol. | No. |
---|---|---|
13.000 | 119 | 1 |
13.050 | 1150 | 1 |
13.180 | 1000 | 1 |
13.200 | 50 | 1 |
13.260 | 1000 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |